CoChat

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date

Open access
Cinti, Francesca, Moffa, Simona, Impronta, Flavia, Cefalo, Chiara Maria Assunta, Sun, Vinsin Alice, Sorice, Gian Pio, Mezza, Teresa, Giaccari, Andrea · 2017 · Drug Design, Development and Therapy
Cited by 91

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients. Keywords: antidiabetic drugs, glycosylated hemoglobin, glycemic control, sodium-glucose cotransporter 2 inhibitors, precision medicine, type 1 diabetes mellitus, type 2 diabetes mellitus, weight reduction

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s114932

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 91

Metadata

Authors
Cinti, F., Moffa, S., Impronta, F., Cefalo, C. M. A., Sun, V. A., Sorice, G. P., Mezza, T., & Giaccari, A.
Venue
Drug Design, Development and Therapy
Published
2017-10
Volume
Volume 11
Pages
2905-2919
ISSN
1177-8881 (ISSN-L)
OpenAlex
W2761588741
Cited by
91
References
12
FWCI
5.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. https://app.cochat.ai/papers/10.2147/dddt.s114932
The paper
Cinti, F., Moffa, S., Impronta, F., Cefalo, C. M. A., Sun, V. A., Sorice, G. P., Mezza, T., & Giaccari, A. (2017). Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s114932

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.